Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Affimed Shares Plunge After Cancer-Drug Study is Put on Hold Following Patient Death

By Catherine Sbeglia | October 9, 2018

Affimed shares dropped 28 percent on Monday following a company announcement that early studies of AFM11 have been put on hold after three patients taking the experimental drug suffered serious adverse events, included one death. The studies were testing the drug in patients with types of non-Hodgkin lymphoma and acute lymphoblastic leukemia.

The company stated that is has notified global health authorities of its decision to put a hold on the studies, and says it will work with regulators, as well as safety monitoring committees and the studies’ clinical investigators, to review the events and determine next steps. 

In a press release, Affimed confirmed that the clinical hold will not affect the ongoing development of the company’s NK cell engager programs, which are based on targeting the NK cell receptor CD16A, a different approach than used for AFM11, which targets T cells through CD3.

AFM11, a CD19/CD3-targeting T cell engager, is being studied in two Phase I trials for the treatment of patients with relapsed or refractory CD19 positive B-cell NHL and ALL. Affimed revealed that the serious adverse events were seen in patients enrolled in the highest dose cohorts of each study.

In total, 33 subjects have been administered AFM11 across the two trials.

(Source: Market Watch; Globe Newswire)


Filed Under: Drug Discovery and Development

 

Related Articles Read More >

Portrait photo of Cardinal Health CFO and soon-to-be CEO Jason Hollar
Cardinal Health’s CFO to move up to corner office
CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50